$-0.86
(Market cap
$339 Mln
Revenue (TTM)
$46 Mln
P/E Ratio
--
P/B Ratio
2.1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-18.1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
41.7
-
Debt to Equity
0
-
Book Value
$-4
-
EPS
$-17.4
-
Face value
--
-
Shares outstanding
16,581,171
8 Years Aggregate
CFO
$-360.12 Mln
EBITDA
$-448.80 Mln
Net Profit
$-479.92 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Sutro Biopharma (STRO)
| 76.8 | -14.8 | -31.1 | 126.3 | -23.7 | -37.7 | -- |
|
BSE Sensex
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Sutro Biopharma (STRO)
| -37.1 | -56.8 | -46.9 | -45.7 | -31.5 | 97.4 | 22.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Sutro Biopharma (STRO)
|
20.5 | 339.1 | 45.7 | -180.6 | -307.8 | -- | -- | 2.1 |
| 84.9 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 247.9 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 72.1 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.5 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 105.4 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 351.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 533.8 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 600.7 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 344.8 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout Sutro Biopharma (STRO)
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific... conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcinoma, endometrial cancer, and bladder cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease in adults and adults and infants; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers. Sutro Biopharma, Inc. has collaboration and license agreements with Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; Ipsen to develop and commercialize STRO-003, an ADC targeting ROR1; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California. Read more
-
CEO & Director
Mr. William J. Newell J.D.
-
CEO & Director
Mr. William J. Newell J.D.
-
Headquarters
South San Francisco, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Sutro Biopharma (STRO)
What is the current share price of Sutro Biopharma (STRO) Today?
The share price of Sutro Biopharma (STRO) is $20.45 (NASDAQ) as of 28-Aug-2026 16:00 EDT. Sutro Biopharma (STRO) has given a return of -23.68% in the last 3 years.
What is the current PB & PE ratio of Sutro Biopharma (STRO)?
Since, TTM earnings of Sutro Biopharma (STRO) is negative, P/E ratio is not available.
The P/B ratio of Sutro Biopharma (STRO) is 2.11 times as on 28-Aug-2026, a 59 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.52 |
-0.75 |
2024 |
-0.07 |
0.34 |
2023 |
-0.25 |
0.17 |
2022 |
-0.38 |
0.21 |
2021 |
-0.65 |
0.27 |
What is the 52 Week High and Low of Sutro Biopharma (STRO)?
The 52-week high and low of Sutro Biopharma (STRO) are Rs 43.85 and Rs 7.15 as of 31-Aug-2026.
What is the market cap of Sutro Biopharma (STRO)?
Sutro Biopharma (STRO) has a market capitalisation of $ 339 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Sutro Biopharma (STRO)?
Before investing in Sutro Biopharma (STRO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.